Dogwood Therapeutics (NASDAQ:DWTX) Issues Quarterly Earnings Results

Dogwood Therapeutics (NASDAQ:DWTX) issued its quarterly earnings data on Thursday. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02, FiscalAI reports. The firm had revenue of $0.10 million during the quarter.

Dogwood Therapeutics Price Performance

NASDAQ DWTX opened at $1.28 on Friday. The firm has a market capitalization of $43.51 million, a P/E ratio of -1.44 and a beta of 2.08. Dogwood Therapeutics has a 1-year low of $0.90 and a 1-year high of $7.04. The business’s 50-day simple moving average is $1.54 and its 200-day simple moving average is $1.95.

Analyst Upgrades and Downgrades

A number of analysts recently commented on DWTX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Dogwood Therapeutics in a report on Thursday, October 22nd. HC Wainwright reaffirmed a “buy” rating on shares of Dogwood Therapeutics in a report on Wednesday, September 2nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Dogwood Therapeutics currently has an average rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with viral activation. The company’s programs are designed to address conditions for which persistent or reactivated viral activity may contribute to symptoms and disease progression.

Its lead investigational product, IMC-1, is an oral combination of the antiviral drug famciclovir and the anti-inflammatory drug celecoxib. The company has evaluated IMC-1 in fibromyalgia and has also investigated its potential use in other conditions, including symptoms associated with long COVID.